leav us
bottom line bristol provid lot inform earn call
relat earn guidanc well regulatori updat
lung cancer front perhap importantli insight
decis acquir celg view combin brist-en
somewhat underwhelm earn guidanc
disappoint lung cancer delay howev thought
compani credibl job walk assumpt
around deal revlimid hold expect celgen
phase asset success make market combin compani
would like better posit next year either bristol
celgen would model modestli
lower sale estim near mid-term also lower
expens reflect compani guidanc leav ep
estim unchang also maintain neutral rate target
price digest detail deal assess whether believ
optim bristol celgen key asset justifi risk
neutral view bristol includ surprisingli posit neg clinic data
readout bristol potenti seen acquisit target
ep driven less import product lower
guidanc slightli top-line updat stand-
alon bristol model reflect compani guidanc call mid-singl
digit top line growth high-singl digit growth mid-singl digit sg
declin top-line adjust decreas revenu
reduc y/i growth driven larg
lower ou sale reflect higher fx headwind lower opdivo
sale lower eliqui sale account
potenti higher rebates/donut hole impact lower revenu off-set
larg lower yoy expens growth
sg
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
pull tmb high file disappoint surpris bristol initi
releas overal surviv hazard ratio tmb high low group
back octob time wonder regul would
approv opdivo yervoy combo regimen nsclc patient tmb high
thought approv might requir clinic data turn
case still believ trial one like
potenti disrupt doctor treat patient lung cancer data
expect suggest combo may real commerci
impact nsclc late
rational brist-en come focu follow confer call
follow call compani better abl understand
bristol assumpt around revlimid longev celgen key pipelin asset
well diversifi compani bristol hope becom complet
celgen deal discuss highlight concentr bristol becom
limit number excit asset stand-alon bristol pipelin see
potenti attract outlook combin compani revlimid hold
compani expect celgen pipelin asset prove
success current pro forma model suggest slightli faster ramp sale
net incom combin compani compar bristol present today
lower sale net incom
sale
net incom
revenu
market sell administr
equiti net incom affili
allianc licens incom
total incom expens
provis incom tax
net incom dilut ep
ms sale
revenu
ep continu oper
compani mention price
